Combining Blinatumomab and Venetoclax with Inotuzumab Ozogamicin for B-ALL Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates a novel treatment regimen for adults with newly diagnosed precursor B-cell acute lymphoblastic leukemia (B-ALL) that combines Blinatumomab, Venetoclax, and Inotuzumab Ozogamicin. The study is a prospective, single-arm, phase II trial aiming to evaluate the safety and efficacy of this multi-drug approach. Participants will undergo induction therapy followed by consolidation and maintenance phases, with a primary endpoint of 2-year event-free survival. The goal is to improve survival rates in this aggressive leukemia population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Before enrollment, a diagnosis of newly diagnosed precursor B-cell acute lymphoblastic leukemia with Philadelphia chromosome-negative must be confirmed. The diagnostic criteria refer to the 2022 WHO classification.
2. Age ≥ 40 years;
3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2;
4. Expected survival time ≥ 3 months;
5. No organ dysfunction that would restrict the use of this protocol during the screening period;
6. Understand the study and sign the informed consent form.
7. Men, women of childbearing age (only postmenopausal women who have been menopausal for at least 12 months can be considered infertile), and their partners voluntarily take effective contraceptive measures deemed effective by the investigator during the treatment period and for at least 12 months after the last dose of the study drug.

Exclusion Criteria:

1. Patients with known central nervous system (CNS) involvement of ALL;
2. Diseases with abnormal heart, lung, liver, kidney, or other organ functions that may limit the patient's participation in this trial (including but not limited to severe infections, uncontrolled diabetes, severe heart failure or angina, active pulmonary tuberculosis, asthma, COPD, bronchiectasis, etc.);
3. Cardiac ultrasound LVEF \< 45%;
4. History of other malignancies within the past 5 years, excluding localized thyroid cancer and in situ skin cancer;
5. Serum total bilirubin \> 1.5 ULN (upper limit of normal); ALT or AST \> 2.5 ULN; serum creatinine \> 1.5 ULN;
6. Known HIV infection;
7. Conditions affecting the use of the study drug as assessed by the investigator;
8. Inability to understand or comply with the study protocol.

Where it's running

• The First Affiliated Hospital, Zhejiang University School of Medicine
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Jie Jin, M.D.
• Email: jiej0503@163.com
• Phone: +8657187236896

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using Brexucabtagene Autoleucel to treat B-cell Acute Lymphoblastic Leukemia after initial therapy

  This study is testing a new CAR-T cell therapy called brexucabtagene autoleucel to see if it can help people with B-cell acute lymphoblastic leukemia who haven't responded to other treatments.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT06287229

• New treatment approach for pediatric patients with relapsed B-cell leukemia

  This study is testing a new combination treatment for kids with relapsed B-cell leukemia to see if it helps them get better and live longer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT05645718

• Inotuzumab ozogamicin and blinatumomab with optional ponatinib for CD22-positive B-cell acute lymphoblastic leukemia

  This trial will test whether inotuzumab ozogamicin followed by blinatumomab, with or without ponatinib, can help people with CD22-positive B-cell acute lymphoblastic leukemia who are newly diagnosed, have relapsed, or are refractory to prior therapy.

  Recruiting at 89 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 284 other locations · NCT03739814

• Using blinatumomab, inotuzumab ozogamicin, and chemotherapy to treat B acute lymphoblastic leukemia

  This study is testing a new combination of two immunotherapy drugs and chemotherapy to see if it helps people with newly diagnosed B acute lymphoblastic leukemia live longer and stay cancer-free.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT02877303

• Blinatumomab plus low-dose donor cells after transplant for high-risk B-ALL

  This small, early-phase study tests whether giving blinatumomab with low-dose donor lymphocytes after allogeneic transplant is safe and helps long-term survival for people with high-risk B-ALL.

  Recruiting Phase 1 Chinese PLA General Hospital · Beijing · NCT07677878

• LP-118 in combination with standard therapy for newly diagnosed Ph+ ALL

  This study tests whether adding LP-118 to the standard therapy for adults with Philadelphia chromosome–positive ALL is safe and useful.

  Recruiting at 2 sites Phase 1 Wake Forest University Health Sciences · Charlotte, North Carolina and 1 other locations · NCT07614022

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.